A Study Of Arginine On Glucagon Secretion In Humans
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 26-008635
About this study
The purpose of this study is to determine the effect of arginine on amino acids-stimulated glucagon secretion and amino acids clearance.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
Obese group with IFG
Aged between 25 and 70 years of age
BMI > 28 Kg/M2 and < 40 Kg/M2
Impaired Fasting Glucose (IFG – fasting glucose >100 but <126 mg/dL)
Reside within a 100-mile radius of Mayo Clinic, Rochester, MN
Control group (Lean)
BMI > 19 Kg/M2 and < 25 Kg/M2
Fasting glucose < 100mg/dL
Reside within a 100-mile radius of Mayo Clinic, Rochester, MN
T1DM group
BMI > 28 Kg/M2 and < 40 Kg/M2
Type 1 diabetes (T1DM)
Reside within a 100-mile radius of Mayo Clinic, Rochester, MN
Obese group with NFG
BMI > 28 Kg/M2 and < 40 Kg/M2
Fasting glucose < 100mg/dL
Reside within a 100-mile radius of Mayo Clinic, Rochester, MM
Exclusion Criteria:
Obese group with IFG
Age < 25 (to ensure that we are not studying subjects with latent type 1 diabetes as people in Olmsted County presenting before age 25 have a high incidence of T1DM) or > 70 years (to avoid extreme age as a factor in islet function)
BMI < 28 Kg/M2 or > 40 Kg/M2
HbA1c > 6.5% or fasting glucose < 100mg/dL or > 126 mg/dL
Use of any glucose-lowering agents
For female subjects: positive pregnancy test at the time of enrollment or study
History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy
Active systemic illness or malignancy
Symptomatic macrovascular or microvascular disease
Control group (Lean)
Age < 25 or > 70 years (to enable matching to the Obese group with IFG)
BMI < 19 Kg/M2 or > 25 Kg/M2
HbA1c > 5.8% or fasting glucose > 100mg/dL.
(Use of any glucose-lowering agents
For female subjects: positive pregnancy test at the time of enrollment or study
History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy
Active systemic illness or malignancy
Symptomatic macrovascular or microvascular disease
T1DM group
Age < 25 or > 70 years (to enable matching to the Obese group with IFG)
BMI < 28 Kg/M2 or > 40 Kg/M2 (to enable matching to the Obese group with IFG)
HbA1c < 5.8 or > 9.0%
Use of any glucose-lowering agents beyond insulin
For female subjects: positive pregnancy test at the time of enrollment or study
History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy
Active systemic illness or malignancy
Symptomatic macrovascular or microvascular disease
Obese group with NFG
Age < 25 or > 70 years (to enable matching to the Obese group with IFG)
BMI < 28 Kg/M2 or > 40 Kg/M2 (to enable matching to the Obese group with IFG)
HbA1c > 5.8% or fasting glucose > 100mg/dL
Use of any glucose-lowering agents
For female subjects: positive pregnancy test at the time of enrollment or study
History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy
Active systemic illness or malignancy
Symptomatic macrovascular or microvascular disease
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 07/21/2026. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Adrian Vella, M.D. |
Contact us for the latest status |
|
More information
Publications
Publications are currently not available